×

Innovative Patient Solutions. Value That Matters.

Learn more about our portfolio of innovative therapies by visiting the product pages.

Product Pipeline

Our advanced science, patented technologies, and innovative approach to drug discovery and development has allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.

SUSTOL® for Chemotherapy-Induced Nausea and Vomiting Prevention (CINV):
U.S. FDA approved as a subcutaneous injection

CINVANTI® for CINV:
U.S. FDA approved as a 30-minute intravenous (IV) infusion and a 2-minute IV injection

ZYNRELEF for Postoperative Pain Management:

  • Marketing Applications Under Review in Canada and Approved in the U.S. and 31 European Countries

HTX-019 for Postoperative Nausea and Vomiting (PONV):

  • Bioequivalence of HTX-019 as a 30-second IV injection demonstrated to approved oral dose of aprepitant for PONV
  • The NDA for HTX-019 for PONV was submitted in November 2021.

HTX-034 for Postoperative Pain Management

Phase 2 clinical study ongoing for postoperative pain via local application into the surgical site

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.

Dev Tool:

Request: product-portfolio
Matched Rewrite Rule: (.?.+?)(?:/([0-9]+))?/?$
Matched Rewrite Query: pagename=product-portfolio&page=
Loaded Template: page.php